Celon Pharma (WAR:CLN) E10: zł0.21 (As of Mar. 2026)


WAR:CLN Celon Pharma SA WAR:CLN
44 GF Score
Price zł19.64
GF Value zł23.16
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma E10?

Celon Pharma WAR:CLN -0.71% 44 E10 is zł0.21 as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 44/100 and a GF Value™ of zł23.16 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Celon Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was zł3.060. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is zł0.21 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-07), Celon Pharma's current stock price is zł19.64. Celon Pharma's E10 for the quarter that ended in Mar. 2026 was zł0.21. Celon Pharma's Shiller PE Ratio of today is 93.52.

During the past 11 years, the highest Shiller PE Ratio of Celon Pharma was 2280.00. The lowest was 94.19. And the median was 101.43.


Celon Pharma  (WAR:CLN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Celon Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=19.64/0.21
=93.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Shiller P/E Ratio of Celon Pharma was 2280.00. The lowest was 94.19. And the median was 101.43.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Celon Pharma E10 Related Terms


Celon Pharma E10 Historical Data

* Premium members only.

The historical data trend for Celon Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma E10 Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.04

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 -0.04 0.21

WAR:CLN vs ZTS, UTHR, VTRS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Shiller PE Ratio falls into.


WAR:CLN
44GF Score
Celon Pharma SA WAR:CLN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celon Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.06/163.0700*163.0700
=3.060

Current CPI (Mar. 2026) = 163.0700.

Celon Pharma Quarterly Data

per share eps CPI Adj_EPS
201606 0.161 99.552 0.264
201609 0.160 99.064 0.263
201612 0.061 100.366 0.099
201703 0.110 101.018 0.178
201706 0.190 101.180 0.306
201709 0.109 101.343 0.175
201712 0.139 102.564 0.221
201803 0.170 102.564 0.270
201806 0.169 103.378 0.267
201809 0.184 103.378 0.290
201812 0.139 103.785 0.218
201903 0.140 104.274 0.219
201906 0.037 105.983 0.057
201909 0.050 105.983 0.077
201912 0.036 107.123 0.055
202003 -0.060 109.076 -0.090
202006 0.080 109.402 0.119
202009 0.040 109.320 0.060
202012 -0.080 109.565 -0.119
202103 -0.040 112.658 -0.058
202106 0.010 113.960 0.014
202109 -0.170 115.588 -0.240
202112 -0.100 119.088 -0.137
202203 -0.150 125.031 -0.196
202206 -0.010 131.705 -0.012
202209 -0.230 135.531 -0.277
202212 -0.240 139.113 -0.281
202303 -0.190 145.950 -0.212
202306 0.180 147.009 0.200
202309 -0.130 146.113 -0.145
202312 -0.290 147.741 -0.320
202403 -0.310 149.044 -0.339
202406 -0.150 150.997 -0.162
202409 1.060 153.439 1.127
202412 -1.260 154.660 -1.329
202503 -0.470 157.021 -0.488
202506 -0.620 157.509 -0.642
202509 0.070 158.000 0.072
202512 -0.480 158.320 -0.494
202603 3.060 163.070 3.060

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of zł0.21 mean?
Celon Pharma (WAR:CLN) has a E10 of zł0.21 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's E10 too high?
Celon Pharma's current E10 is zł0.21. Overall, Celon Pharma has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's E10 compare to ZTS and UTHR?
Celon Pharma's E10 of zł0.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Celon Pharma and its competitors. Celon Pharma's current E10 is zł0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.16, compared to a current price of zł19.64 — trading 15.2% below its estimated fair value. The current E10 is zł0.21. Celon Pharma's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current E10 is zł0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.64 is trading 15.2% below its estimated GF Value™ of zł23.16. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • E10: zł0.21
  • GF Value™: zł23.16 vs. price of zł19.64 (15.2% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
44GF Score

Get the complete analysis for WAR:CLN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.64
Price
zł23.16
GF Value